<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20110629006922N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-05-28</date_registration>
      <primary_sponsor>Zanjan University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Oral Midazolam in Pain relief</public_title>
      <acronym></acronym>
      <scientific_title>Effect of Oral Midazolam in Pain relief of patients need Nasogastric Tube insertion:A Clinical Trial Study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>200</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/39705</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: Due to the presence of pain during insertion of NG Tube and its intolerance in many patients, and the lack of a positive clinical response to thrombocytopenia with lidocaine, as well as the side effects and limitations related to intravenous ketamine and midazolam, we decided This study was conducted to evaluate the effects of oral midazolam in relieving pain in patients requiring ease of administration of NG Tube, Randomization description: Patients are divided into 2-person blocks based on a Random Software Allocation Software (RAS) program, then the two case groups (Midazolam receiving group) and the control group (the group receiving the placebo) will be defined in the software, Blinding description: Patients are randomly divided into two groups based on RAS software. Prepared syrups with the dosage calculated from midazolam and placebo were delivered to the person responsible for the NG Tube and will be administered orally, 20 minutes before the procedure, with a mild administration dose (2 mg).
Containers containing midazolam and placebo are pre-coded so that the relevant assistant, patient and NG Tube employs the contents of the dishes. And the placebo is used in terms of color, odor, and appearance of the drug.</study_design>
      <phase>3</phase>
      <hc_freetext>Effect of oral midazolam on Reduce pain in the time of nasogastric insertion.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Midazolam receiving group;       Midazolam syrup, which was made by professors of Pharmacology Department of Tabriz University of Medical Sciences. This syrup is given orally to a patient at a dose of 2 mg 20 minutes before the nasogastric tube is inserted. After insertion, it will be questioned about the severity of pain and the satisfaction of the insertion of this tube. Intervention 2: Control group: Group receiving placebo.                                                       Placebo syrup was also made by professors of the Pharmacology Department of Tabriz University of Medical Sciences. The placebo syrup is quite similar to midazolam and its mode of administration is similr midazolam. This syrup is given orally to a patient at a dose of 2 mg 20 minutes before the nasogastric tube is inserted. After insertion, it will be questioned about the severity of pain and the satisfaction of the insertion of this tube.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The whole data after Unidentifiable of patients, will be converted into the article and we try to published it in a reliable Journal

When:
All data will be released without time limitation.

To whom:
Results will be available for all groups.

Conditions:
Data will be available to interested researchers without limitations.

Where to obtain:
In order to receive the dataو during communication with the responsible scientific officer, the requested information will be provided to the applicants through his email.

How to obtain:
With request for Information, it will be sent by email as soon as possible.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ala Rastin</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Valiasr Hospital; Valiasr square; Zanjan; Iran</address>
        <city>Zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4515777977</zip>
        <telephone>+98 24 3377 0801</telephone>
        <email>ala.rastin@gmail.com</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ala Rastin</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emergency Department; Valiasr Hospital; Valiasr square; Zanjan; Iran</address>
        <city>Zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4515777977</zip>
        <telephone>+98 24 3377 0801</telephone>
        <email>Ala.rastin@gmail.com</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>patients with age 18 - 60 years
Indication for Nasogatric tube insertion ( treatment - diagnostic)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>decrease level of consciousness
allergy to benzodiazepines
difficulty of swalloing
nausea or vomiting
chronic obstructive pulmonary disease
pregnancy
breastfeeding
hypotension ( systolic blood pressure below 90 )
Dissatisfied to participate in the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Y47</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Sedatives, hypnotics and antianxiety drugs</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Midazolam receiving group;       Midazolam syrup, which was made by professors of Pharmacology Department of Tabriz University of Medical Sciences. This syrup is given orally to a patient at a dose of 2 mg 20 minutes before the nasogastric tube is inserted. After insertion, it will be questioned about the severity of pain and the satisfaction of the insertion of this tube.</i_keyword>
      <i_keyword>Control group: Group receiving placebo.                                                       Placebo syrup was also made by professors of the Pharmacology Department of Tabriz University of Medical Sciences. The placebo syrup is quite similar to midazolam and its mode of administration is similr midazolam. This syrup is given orally to a patient at a dose of 2 mg 20 minutes before the nasogastric tube is inserted. After insertion, it will be questioned about the severity of pain and the satisfaction of the insertion of this tube.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain sensation in visual analog score. Timepoint: Time of nasogastric insertion. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Satisfaction with Nasogastric tube insertion. Timepoint: After nasogastric tube insertion. Method of measurement: Visual analogue scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zanjan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-10-15</approval_date>
        <contact_name>Ethics committee of Zanjan University of Medical Sciences</contact_name>
        <contact_address>Valiasr Square; Sheikh Fazlollah Noori Highway; Educational &amp; Therapeutic Valiasr Center Zanjan Zanjan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
